PK

DIAGNOSTIC_TEST2 trials

Sponsors

Drugs for Neglected Diseases, Kamari Pharma Ltd

Conditions

Neonatal SEPSISPachyonychia CongenitaPunctate Palmoplantar Keratoderma Type 1

Phase 1

Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases

CompletedNCT05435638

Kamari Pharma LtdPachyonychia Congenita, Punctate Palmoplantar Keratoderma Type 1

Start: 2022-07-17End: 2024-09-05Updated: 2025-01-07

Phase 2

Intravenous and Oral Fosfomycin in Hospitalised Neonates With Clinical Sepsis

CompletedNCT03453177

Drugs for Neglected DiseasesNeonatal SEPSIS

Start: 2018-03-15End: 2019-05-24Updated: 2020-02-17

Related Papers

Randomised controlled trial of fosfomycin in neonatal sepsis: pharmacokinetics and safety in relation to sodium overload

Archives of Disease in Childhood2022-01-2521 citations

Simultaneous pharmacokinetic/pharmacodynamic (PKPD) assessment of ampicillin and gentamicin in the treatment of neonatal sepsis

Journal of Antimicrobial Chemotherapy2021-10-226 citations

IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis

Journal of Antimicrobial Chemotherapy2021-03-0829 citations